El procesamiento de palabras en una segunda lengua: evidencia conductual y electrofisiológica

[ES]En el mundo globalizado en el que vivimos, cada vez es más común que las personas hablen más de una lengua. La presente Tesis Doctoral se centra en comprender cómo personas que tienen una competencia moderada en su segunda lengua (L2) procesan palabras en esta lengua, en comparación con su primera lengua (L1). Específicamente, la parte experimental de este trabajo expone tres experimentos que tratan de comprender cómo se produce la activación de los conceptos en la memoria semántica a partir de palabras en la L1 y la L2 y cómo dicha activación se propaga por la red asociativa según el grado de asociación entre los conceptos

5 minutos de Psicología: Desarrollo de competencias de comunicación lingüística a través de la divulgación científica de la Psicología

Memoria ID-180. Ayudas de la Universidad de Salamanca para la innovación docente, curso 2019-2020

Desarrollo e implementación de una nueva metodología para el desarrollo de competencias de comunicación: aprender haciendo

Memoria ID-125. Ayudas de la Universidad de Salamanca para la innovación docente, curso 2020-2021

Implementación de una metodología participativa en el estudio de los procesos cognitivos básicos desde las técnicas de electroencefalografía

Memoria ID-158. Ayudas de la Universidad de Salamanca para la innovación docente, curso 2018-2019

Inhibidores selectivos de la monoamino oxidasa. 1. Hidracinas de formilimidazoles 1-sustitudos

Se ha preparado una serie de hidracinometilimidazoles I-sustituidos y estudiado su actividad IMAO. Los ensayos in vitro revelan que los I-arilimidazoles son inhibidores selectivos de la MAO A a bajas concentraciones.A series of hydrazinomethylimidazole I-sustituted was prepared and evaluated for their monoamine oxidase (MAO) inhibitory activity. In vitro testing revealed that the 1- arylimidazole derivatives were selectively inhibitors of MAO A at low concentrations

Lymphangioleiomyomatosis biomarkers linked to lung metastatic potential and cell stemness

Lymphangioleiomyomatosis (LAM) is a rare lung-metastasizing neoplasm caused by the proliferation of smooth muscle-like cells that commonly carry loss-of-function mutations in either the tuberous sclerosis complex 1 or 2 (TSC1 or TSC2) genes. While allosteric inhibition of the mechanistic target of rapamycin (mTOR) has shown substantial clinical benefit, complementary therapies are required to improve response and/or to treat specific patients. However, there is a lack of LAM biomarkers that could potentially be used to monitor the disease and to develop other targeted therapies. We hypothesized that the mediators of cancer metastasis to lung, particularly in breast cancer, also play a relevant role in LAM. Analyses across independent breast cancer datasets revealed associations between low TSC1/2 expression, altered mTOR complex 1 (mTORC1) pathway signaling, and metastasis to lung. Subsequently, immunohistochemical analyses of 23 LAM lesions revealed positivity in all cases for the lung metastasis mediators fascin 1 (FSCN1) and inhibitor of DNA binding 1 (ID1). Moreover, assessment of breast cancer stem or luminal progenitor cell biomarkers showed positivity in most LAM tissue for the aldehyde dehydrogenase 1 (ALDH1), integrin-ß3 (ITGB3/CD61), and/or the sex-determining region Y-box 9 (SOX9) proteins. The immunohistochemical analyses also provided evidence of heterogeneity between and within LAM cases. The analysis of Tsc2-deficient cells revealed relative over-expression of FSCN1 and ID1; however, Tsc2-deficient cells did not show higher sensitivity to ID1-based cancer inhibitors. Collectively, the results of this study reveal novel LAM biomarkers linked to breast cancer metastasis to lung and to cell stemness, which in turn might guide the assessment of additional or complementary therapeutic opportunities for LAM

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality

Adelante / Endavant

Séptimo desafío por la erradicación de la violencia contra las mujeres del Institut Universitari d’Estudis Feministes i de Gènere "Purificación Escribano" de la Universitat Jaume